LYRA vs XNCR vs ABBV vs REGN vs CRL

For growth investors, Xencor, Inc.

(XNCR) is the stronger pick with 13. 7% revenue growth year-over-year, versus -1. 5% for Lyra Therapeutics, Inc. (LYRA). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 1x trailing P/E (15. 5x forward), making it the more compelling value choice. Analysts rate Xencor, Inc. (XNCR) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 17. 1x versus AbbVie Inc. at 85. 5x. On forward P/E, AbbVie Inc. is actually cheaper at 14. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +101. 3%, compared to -99. 9% for Lyra Therapeutics, Inc. (LYRA). Over 10 years, the gap is even starker: ABBV returned +293. 8% versus LYRA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 28β versus Xencor, Inc. 's 1. 80β — meaning XNCR is approximately 552% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 3% for Lyra Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Xencor, Inc.

(XNCR) is pulling ahead at 13. 7% versus -1. 5% for Lyra Therapeutics, Inc. (LYRA). On earnings-per-share growth, the picture is similar: Xencor, Inc. grew EPS 65. 4% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, LYRA leads at 75. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -60. 9% for Lyra Therapeutics, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -62. 8% for LYRA. At the gross margin level — before operating expenses — LYRA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, AbbVie Inc.

(ABBV) trades at 14. 2x forward P/E versus 16. 0x for Charles River Laboratories International, Inc. — 1. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for XNCR: 123. 4% to $27. 50.

In this comparison, ABBV (3.

2% yield), REGN (0. 5% yield) pay a dividend. LYRA, XNCR, CRL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 28), 3. 2% yield, +293. 8% 10Y return). Xencor, Inc. (XNCR) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +293. 8%, XNCR: +9. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LYRA is a small-cap quality compounder stock; XNCR is a small-cap quality compounder stock; ABBV is a large-cap income-oriented stock; REGN is a mid-cap deep-value stock; CRL is a small-cap quality compounder stock. ABBV pays a dividend while LYRA, XNCR, REGN, CRL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.